View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Combino Pharm Malta
26 September 2012

Combino Pharm: Memantine, a New Business Opportunity

Combino Pharm presents a new business opportunity with the product Memantine.

1. Product Description: memantine hydrochloride

2. Therapeutical indication: treatment of patients with moderate to severe Alzheimer’s disease.

3. Presentation: film-coated tablets of 10mg.

4. Highlights:

  • FDF produced in our manufacturing facility in Malta
  • DCP slot in DE available in May 2012

5. Patent status: European alzheimer use patent until 14/04/2014.

6. Regulatory details:

  • API Supplier: EU
  • DF: Combino Pharm Malta

7. Regulatory Strategy: dossier completed and submission in May 2012 as a national procedure in PT.

Combino Pharm: Alcoholic Clorhexidine Coloured and Aqueous Clorhexidine Transparent
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology